Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.79 -3.2%	$1.56	$1.05 ▼ $5.17	$200.41M	0.3	1.47 million shs	995,478 shs
NAGE Niagen Bioscience	$9.63 -4.8%	$11.43	$3.10 ▼ $14.69	$807.10M	2.12	1.29 million shs	741,581 shs
NRIX Nurix Therapeutics	$9.84 -3.5%	$11.55	$8.18 ▼ $29.56	$780.17M	2.14	744,720 shs	743,728 shs
PHAR Pharming Group	$12.58 +1.5%	$10.90	$6.73 ▼ $17.08	$848.90M	0.02	11,183 shs	11,712 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	-1.07%	+12.80%	+14.91%	+37.04%	+55.46%
NAGE Niagen Bioscience	+1.00%	+3.05%	-0.39%	-5.95%	+202.99%
NRIX Nurix Therapeutics	-3.59%	+5.70%	-9.01%	+0.59%	-54.22%
PHAR Pharming Group	+6.35%	+2.40%	+20.64%	+23.47%	+59.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.6833 of 5 stars	3.6	3.0	2.1	1.7	0.6
NAGE Niagen Bioscience	1.3378 of 5 stars	3.5	0.0	1.9	0.0	0.0
NRIX Nurix Therapeutics	2.3515 of 5 stars	4.4	2.0	1.4	0.8	0.0
PHAR Pharming Group	2.1277 of 5 stars	3.5	3.0	1.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$8.71	386.83% Upside
NAGE Niagen Bioscience	3.00	Buy	$13.42	39.36% Upside
NRIX Nurix Therapeutics	2.81	Moderate Buy	$28.87	193.36% Upside
PHAR Pharming Group	3.00	Buy	$30.00	138.47% Upside

Current Analyst Ratings Breakdown

Latest ACRS, NRIX, NAGE, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	NAGE Niagen Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
7/31/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $16.00
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
7/10/2025	ACRS Aclaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $26.00
7/10/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/10/2025	NRIX Nurix Therapeutics	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00
6/25/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/23/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
6/10/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $16.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$18.72M	10.36	N/A	N/A	$1.22 per share	1.47
NAGE Niagen Bioscience	$99.60M	7.71	$0.06 per share	171.09	$0.80 per share	12.04
NRIX Nurix Therapeutics	$54.55M	13.79	N/A	N/A	$7.44 per share	1.32
PHAR Pharming Group	$297.20M	2.90	$0.08 per share	167.14	$3.50 per share	3.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.37	N/A	N/A	N/A	-802.03%	-34.01%	-24.18%	11/5/2025 (Estimated)
NAGE Niagen Bioscience	$8.55M	$0.21	77.85	∞	N/A	15.24%	23.12%	15.53%	N/A
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	10/10/2025 (Estimated)
PHAR Pharming Group	-$11.84M	-$0.13	N/A	419.33	N/A	-2.19%	-3.31%	-1.78%	10/23/2025 (Estimated)

Latest ACRS, NRIX, NAGE, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ACRS Aclaris Therapeutics	-$0.13	-$0.13	N/A	-$0.13	$1.34 million	$1.78 million
8/6/2025	Q2 2025	NAGE Niagen Bioscience	$0.02	$0.04	+$0.02	$0.04	$28.55 million	$31.12 million
7/31/2025	Q2 2025	PHAR Pharming Group	-$0.10	$0.06	+$0.16	$0.06	$70.36 million	$93.20 million
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44,056.00 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.88	3.88
NAGE Niagen Bioscience	N/A	3.88	3.24
NRIX Nurix Therapeutics	N/A	6.82	6.82
PHAR Pharming Group	0.38	2.79	2.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
NAGE Niagen Bioscience	15.41%
NRIX Nurix Therapeutics	N/A
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	5.60%
NAGE Niagen Bioscience	9.39%
NRIX Nurix Therapeutics	7.40%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.33 million	102.27 million	Optionable
NAGE Niagen Bioscience	120	79.75 million	72.26 million	N/A
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable
PHAR Pharming Group	280	68.51 million	67.10 million	Not Optionable

ACRS, NRIX, NAGE, and PHAR Headlines

Recent News About These Companies

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short Interest

August 17 at 10:28 AM | marketbeat.com

Pharming Group (NASDAQ:PHAR) Trading 1.2% Higher - Still a Buy?

August 16 at 3:35 AM | marketbeat.com

Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Should You Buy?

August 13, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?

August 12, 2025 | marketbeat.com

Pharming Group NV (PHARMA.XD) - Yahoo Finance

August 10, 2025 | finance.yahoo.com

Pharming Group (NASDAQ:PHAR) Hits New 1-Year High - Still a Buy?

August 7, 2025 | marketbeat.com

Wall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a Bet

August 6, 2025 | zacks.com

Pharming Group (NASDAQ:PHAR) Trading Up 7.9% - Should You Buy?

August 5, 2025 | marketbeat.com

Pharming Group N.V. Reports Strong Q2 Earnings

August 4, 2025 | theglobeandmail.com

Pharming Group to participate in August investor conference

August 4, 2025 | uk.finance.yahoo.com

Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume Following Better-Than-Expected Earnings

August 2, 2025 | marketbeat.com

Pharming Group Second Quarter 2025 Earnings: EPS: US$0.007 (vs US$0.002 loss in 2Q 2024)

August 2, 2025 | finance.yahoo.com

Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript

August 1, 2025 | seekingalpha.com

Pharming Group N.V. 2025 Q2 - Results - Earnings Call Presentation

August 1, 2025 | seekingalpha.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up After Better-Than-Expected Earnings

August 1, 2025 | marketbeat.com

New Strong Buy Stocks for August 1st

August 1, 2025 | zacks.com

Pharming Group reports second quarter and first half 2025 financial results and provides business update

July 31, 2025 | finance.yahoo.com

High Growth Tech Stocks To Watch In Europe July 2025

July 29, 2025 | finance.yahoo.com

Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Still a Buy?

July 26, 2025 | marketbeat.com

Best Momentum Stocks to Buy for July 25th

July 25, 2025 | zacks.com

New Strong Buy Stocks for July 25th

July 25, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ACRS, NRIX, NAGE, and PHAR Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.79 -0.06 (-3.24%)

Closing price 04:00 PM Eastern

Extended Trading

$1.77 -0.02 (-1.06%)

As of 07:57 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Niagen Bioscience NASDAQ:NAGE

$9.63 -0.49 (-4.84%)

As of 04:00 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Nurix Therapeutics NASDAQ:NRIX

$9.84 -0.36 (-3.53%)

Closing price 04:00 PM Eastern

Extended Trading

$9.83 -0.01 (-0.10%)

As of 07:30 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Pharming Group NASDAQ:PHAR

$12.58 +0.19 (+1.53%)

Closing price 03:56 PM Eastern

Extended Trading

$12.44 -0.15 (-1.15%)

As of 07:31 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time